The Knockout Mouse Project (KOMP) is a trans-NIH
initiative that aims to generate a comprehensive and public resource comprised of mouse embryonic
stem (ES) cells containing a null mutation in every gene in the mouse genome.
The NIH KOMP initiative aims to:
- use gene targeting to make the resource of null alleles, marked with a high utility reporter,
preferably in C57BL/6;
- support a repository to house the products of this resource as well as an additional
repatriation' effort to bring into repositories 1000 of the
existing high priority mouse knockouts not already stored in a public repository;
- develop improved C57BL/6 ES cells that show robust germline transmission, so that they may be
used in a high throughput pipeline in generating this
- implement a data coordination center which will make the status and relevant data of the
production effort available to the research community.
Towards those ends, NIH awarded five-year cooperative agreements totaling up to $47.2 million to two groups
for the creation of the knockout mice lines.
Recipients of those awards are Velocigene,
a division of Regeneron Pharmaceuticals, Inc., in Tarrytown, N.Y., and
a collaborative team from Children's Hospital Oakland
Research Institute (CHORI) in Oakland, Calif.,
the School of Veterinary Medicine, University of
California, Davis (UC Davis); and
the Wellcome Trust Sanger Institute
in Hinxton, England.
Under its cooperative agreement, the team led by Pieter deJong, Ph.D., CHORI, along with K. C. Kent Lloyd,
D.V.M., Ph.D., UC Davis; and Allan Bradley, Ph.D. FRS, and William Skarnes, Ph.D., at the Wellcome Trust
Sanger Institute, plans to systematically create mouse ES cell lines in which 5,000 genes have been knocked
out by gene targeting.
The VelociGene division of Regeneron, led by David Valenzuela, Ph.D. and George D. Yancopoulos, M.D., Ph.D.,
will take aim at a different set of 3,500 genes.
Both groups will utilize information from the finished mouse genome sequence to design targeting vectors,
which will be built by large-scale, automated
The combined collection of mouse ES cells with knockouts in 8,500 genes will be useful for producing
In addition, NIH awarded another five-year cooperative agreement totaling $2.5 million to Mouse Genome
Informatics (MGI) to set up a
Data Coordination Center
for the Knockout Mouse Project.
The center will collect information that will allow the research community to track the scheduling and
progress of knockout production.
The NIH also awarded cooperative agreements to the
University of Pennsylvania in Philadelphia and to the
Samuel Lunenfeld Research Institute of Mount Sinai
Hospital in Toronto to improve the efficiency of methods for creating knockout lines.
Finally, in June 2007, NIH announced it will provide $4.8 million to establish and support a repository for
its Knockout Mouse Project. This award is the final component of a more than $50 million trans-NIH
initiative to increase the availability of genetically altered mice and related materials. The University of
California, Davis (UC Davis) and Children's Hospital Oakland Research Institute (CHORI) in Oakland, Calif.,
will collaborate to preserve, protect, and make available about 8,500 types of knockout mice and related
products available to the research community.
The 19 NIH institutes, centers and offices contributing to the Knockout Mouse Project are:
- National Center for Research Resources,
- National Eye Institute,
- National Heart, Lung and Blood Institute,
- National Institute on Aging,
- National Institute of Alcohol Abuse and Alcoholism,
- National Institute of Allergy and Infectious Diseases,
- National Institute of Arthritis and Musculoskeletal and Skin Diseases,
- National Institute of Child Health and Human Development,
- National Institute on Deafness and Other Communication Disorders,
- National Institute of Dental and Craniofacial Research,
- National Institute of Environmental Health Sciences,
- National Institute of General Medical Sciences,
- National Institute of Mental Health,
- National Institute of Neurological Disorders and Stroke,
- National Institute of Diabetes and Digestive and Kidney Disease,
- National Cancer Institute, and the
- Office of AIDS Research.
For more information on KOMP, go to the NIH's website at